CoChat

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Open access
Zinman, Bernard, Philis-Tsimikas, Athena, Cariou, Bertrand, Handelsman, Yehuda, Rodbard, Helena W., Johansen, Thue, Endahl, Lars, Mathieu, Chantal, on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators · 2012 · Diabetes Care

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS: In this 1-year, parallel-group, randomized, open-label, treat-to-target trial, adults with type 2 diabetes with A1C of 7−10% taking OADs were randomized 3:1 to receive once daily degludec or glargine, both with metformin. Insulin was titrated to achieve prebreakfast plasma glucose (PG) of 3.9−4.9 mmol/L. The primary end point was confirmation of noninferiority of degludec to glargine in A1C reduction after 52 weeks in an intent-to-treat analysis. RESULTS: In all, 1,030 participants (mean age 59 years; baseline A1C 8.2%) were randomized (degludec 773, glargine 257). Reduction in A1C with degludec was similar (noninferior) to that with glargine (1.06 vs. 1.19%), with an estimated treatment difference of degludec to glargine of 0.09% (95% CI −0.04 to 0.22). Overall rates of confirmed hypoglycemia (PG <3.1 mmol/L or severe episodes requiring assistance) were similar, with degludec and glargine at 1.52 versus 1.85 episodes/patient-year of exposure (PYE). There were few episodes of nocturnal confirmed hypoglycemia in the overall population, and these occurred at a lower rate with degludec versus glargine (0.25 vs. 0.39 episodes/PYE; P = 0.038). Similar percentages of patients in both groups achieved A1C levels <7% without hypoglycemia. End-of-trial mean daily insulin doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Adverse event rates were similar. CONCLUSIONS: Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-1205

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Glycemic efficacy. A: Mean A1C with time. B: Mean fasting PG with time. C: Nine-point profiles of SMBG at baseline (week 0) and after 52 weeks. Data for the first seven points are obtained on one day and data for the remaining two points are drawn from the next day. Data are reported as the mean ± SEM. Missing data after baseline were imputed with the last observation carried forward approach. Ideg, insulin degludec; IGlar, insulin glargine; od, once daily.
Figure 1 Glycemic efficacy. A: Mean A1C with time. B: Mean fasting PG with time. C: Nine-point profiles of SMBG at baseline (week 0) and after 52 weeks. Data for the first seven points are obtained on one day and data for the remaining two points are drawn from the next day. Data are reported as the mean ± SEM. Missing data after baseline were imputed with the last observation carried forward approach. Ideg, insulin degludec; IGlar, insulin glargine; od, once daily.CC BY-NC-ND · PubMed Central
Figure 2 Confirmed hypoglycemic episodes. A: Overall confirmed hypoglycemic episodes. B: Nocturnal confirmed hypoglycemic episodes. See methodology for plotting graph in the Supplementary Data online. IDeg, insulin degludec; IGlar, insulin glargine; od, once daily.
Figure 2 Confirmed hypoglycemic episodes. A: Overall confirmed hypoglycemic episodes. B: Nocturnal confirmed hypoglycemic episodes. See methodology for plotting graph in the Supplementary Data online. IDeg, insulin degludec; IGlar, insulin glargine; od, once daily.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. International Diabetes foundation. Diabetes atlas 5th edition [article online], 2011. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 10 January 2012
  2. Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state (Abstract), Diabetes, 60, A263

Cited by

Metadata

Authors
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators
Affiliations
  • Mount Sinai Hospital (CA)
  • Scripps Whittier Diabetes Institute, La Jolla, California
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Metabolic Institute of America, Tarzana, California
  • Endocrine and Metabolic Consultants, Rockville, Maryland
  • Novo Nordisk (Denmark) (DK)
  • Universitair Ziekenhuis Leuven (BE)
Corresponding author
Mathieu, Chantal
Venue
Diabetes Care
Published
2012-11-14
Volume
35
Issue
12
Pages
2464-2471
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1965832529
Cited by
336
References
34
Citations by year
2026: 3 · 2025: 9 · 2024: 12 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 17 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 30 · 2015: 41 · 2014: 42 · 2013: 35 · 2012: 4
FWCI
31.31
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, other-oa)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • Amarin Corporation
  • MannKind Corporation
  • Halozyme
  • Novo Nordisk
  • Genentech
  • Merck Sharp and Dohme
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin degludec, insulin glargine, type 2 diabetes, insulin-naive patients, ultra-long-acting insulin, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, metformin, oral antidiabetic drugs, insulin dose, non-inferiority, treat-to-target, insulin dose adjustment, adverse events
MeSH terms
Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.